Exosome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Exosome Type (Natural v/s Hybrid), By Source (Mesenchymal Stem Cells, Blood, Body Fluids, Others), By Therapy (Immunotherapy, Chemotherapy, Gene Therapy), By Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Others), By End User (Hospitals & Clinics, Academi
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationExosome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Exosome Type (Natural v/s Hybrid), By Source (Mesenchymal Stem Cells, Blood, Body Fluids, Others), By Therapy (Immunotherapy, Chemotherapy, Gene Therapy), By Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Others), By End User (Hospitals & Clinics, Academi
According to clinicaltrials.gov, currently, there are 25 clinical trials related to exosome therapeutics going on worldwide that are in different phases of development.
Increasing Prevalence of Chronic Diseases
the total number of 2,281,658 effected skin cancer diseases across the globe 4.2% are effected in melanoma skin cancer, 6.8% are effected in colorectum cancer, 9.2% are effected in prostate cancer, 10% are effected in lung cancer, 11.1% are effected in breast cancer and 58.7% are effected in other cancer.
Growing research and development
According to American Cancer Society, , in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.
Recent Development
- In 2021, Evox Therapeutics launched the EVOGENE® Exosome RNA Delivery System, a platform that utilizes exosomes for the targeted delivery of RNA therapeutics. The system is designed to improve the efficacy and safety of RNA therapeutics by delivering them directly to specific cells or tissues.
- In 2019, Exosome Diagnostics launched the ExoDx Prostate IntelliScore (EPI) test, a liquid biopsy test that analyzes exosomes in urine samples to determine the likelihood of high-grade prostate cancer. The test offers a non-invasive alternative to traditional diagnostic methods, and has the potential to improve patient outcomes by identifying cancer earlier.
- In 2018, Exopharm launched the Plexarisâ„¢ exosome isolation and purification system, a tool for the rapid and efficient isolation of exosomes from biological samples. The system utilizes a proprietary technology to isolate and purify exosomes without the need for ultracentrifugation or other complex methods, and is designed to facilitate research and development in the field of exosome therapeutics.
Download Free Sample Report
Market Segmentation
In terms of country, the United States is expected to be a lucrative market in the forecast period as the government is investing in new exosome therapeutics for the easy detection of chronic disease unaffected people.
Market Players
Aethlon Medical, Inc.-Exosome Sciences, Aegle Therapeutics, Anjarium Biosciences AG, Exogenus Therapeutics SA, Lonza Group, Capricor Therapeutics, Inc., Avalon Globocare Corp, Stem Cell Medicine Ltd., Evox Therapeutics Limited, EV Therapeutics are some of the leading players operating in the global exosome therapeutics market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · By Exosome Type · By Source · By Therapy · By Application · By End User |
| Regional scope | North America; Asia Pacific; Europe; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; China; India; Japan; South Korea; Australia; Germany; France; United Kingdom; Italy; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; |
| Key companies profiled | Aethlon Medical, Inc.-Exosome Sciences, Aegle Therapeutics, Anjarium Biosciences AG, Exogenus Therapeutics SA, Lonza Group, Capricor Therapeutics, Inc., Avalon Globocare Corp, Stem Cell Medicine Ltd., Evox Therapeutics Limited, EV Therapeutics |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy